Medtronic and Tidepool, a nonprofit organization dedicated to making diabetes data more accessible, actionable and meaningful, have agreed to work together to create an interoperable automated insulin pump system.
Medtronic will develop a future Bluetooth-enabled MiniMed pump that would be compatible with Tidepool Loop, a future FDA-regulated, open source automated insulin delivery app for iPhone and Apple Watch currently in development.
As part of the agreement, Medtronic will contribute financial support to Tidepool for the integration development effort and develop a software development kit to enable iPhone to pump communication. Both companies will be work closely with the Food and Drug Administration (FDA) through the regulatory process to garner approvals for both the Tidepool Loop app and the future Bluetooth-enabled MiniMed pump that will work with Tidepool Loop. This includes pursuing iCGM (Integrated Continuous Glucose Monitoring) classification for the Guardian Sensor 3 and ACE (Alternate Controller Enabled) pump classification for a future Bluetooth-enabled MiniMed pump. This would enable an FDA-cleared interoperable system – with ACE pump and iCGM sensor components – that may be mixed and matched with the Tidepool Loop app as the user chooses.
Tidepool Loop will be an automated insulin delivery app for iPhone and Apple Watch that connects to an insulin pump and CGM using Bluetooth LE. It runs an algorithm every five minutes to adjust a user’s basal rate for the next 30 minutes, with the goal to help reduce or avoid high and low blood glucose. Tidepool intends to deliver Tidepool Loop as an FDA-regulated product, broadly available via the iOS App Store, compatible with multiple, in-warranty pumps and CGMs.